BioCentury
ARTICLE | Clinical News

OncoQuest begins Phase Ib/IIa of oregovomab in ovarian cancer

May 17, 2017 9:01 PM UTC

Quest PharmaTech Inc. (TSX-V:QPT) subsidiary OncoQuest Inc. began the Phase Ib/IIa ORION-01 trial to evaluate oregovomab (OvaRex Mab, OvaRex) plus Opdivo nivolumab in about 32 patients with recurrent epithelial ovarian cancer who have progressed after ≥2 prior lines of chemotherapy. The open-label, Singaporean trial will evaluate 0.5, 1 and 2 mg IV oregovomab every 4 weeks plus Opdivo every 2 weeks for up to 36 months.

The co-primary endpoints of the trial are safety, overall response rate (ORR) and progression-free survival (PFS). The trial’s secondary endpoints are ORR as per immune-related criteria and in epithelial ovarian cancer subtypes, disease control rate (DCR) and overall survival (OS)...

BCIQ Company Profiles

Quest PharmaTech Inc.

BCIQ Target Profiles

CA 125